title: Bariatric surgery for type 2 diabetes: weighing the impact for obese patients.
abstract: Obesity is a potent risk factor for the development and progression of type 2 diabetes, and weight loss is a key component of diabetes management. Bariatric surgery results in significant weight loss and remission of diabetes in most patients. After surgery, glycemic control is restored by a combination of enforced caloric restriction, enhanced insulin sensitivity, and increased insulin secretion.
authors.affiliation: Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic, Cleveland, OH 44195, USA. kashyas@ccf.org
authors.forename: Sangeeta R
authors.initials: SR
authors.lastname: Kashyap
authors.forename: Patrick
authors.initials: P
authors.lastname: Gatmaitan
authors.forename: Stacy
authors.initials: S
authors.lastname: Brethauer
authors.forename: Philip
authors.initials: P
authors.lastname: Schauer
mesh_terms: D050110:Bariatric Surgery / Q000706:statistics & numerical data*; D015992:Body Mass Index; D031204:Caloric Restriction; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology / Q000601:surgery*; D019468:Disease Management; D018450:Disease Progression; D015390:Gastric Bypass / Q000379:methods / Q000706:statistics & numerical data; D005749:Gastric Inhibitory Polypeptide / Q000378:metabolism; D052216:Glucagon-Like Peptide 1 / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D000078790:Insulin Secretion; D012307:Risk Factors; D015431:Weight Loss
chemical_list: D007328:Insulin; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1